Health-related quality of life and treatment satisfaction in the sensor-augmented pump therapy for A1C reduction 3 (STAR 3) trial

Diabetes Technology and Therapeutics

Volumn 14, Issue 2, 2012, Pages 143-151

  Rubin, Richard R ^a   Peyrot, Mark ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOYOLA UNIVERSITY MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN ASPART; INSULIN GLARGINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOSENSOR; CAREGIVER; CHILD; CONTROLLED STUDY; DRUG USE; FEAR; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIPLE DAILY INJECTION THERAPY; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SELF MONITORING; SENSOR AUGMENTED PUMP THERAPY; SHORT FORM 36; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANXIETY; BLOOD GLUCOSE SELF-MONITORING; CAREGIVERS; CHILD; CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMPUTER-ASSISTED; FEMALE; HEALTH STATUS; HUMANS; HYPOGLYCEMIC AGENTS; INFUSION PUMPS, IMPLANTABLE; INSULIN; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; YOUNG ADULT;

EID: 84855840292     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0162     Document Type: Article

References (23)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
2. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDICT) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
3. Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J: Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010;1:CD005103.
4. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464-1476.
5. Hirsch IB, Abelseth J, Bode BW, Fischer J, Kaufman FR, Mastrototaro J, Parkin CG, Wolpert HA, Buckingham BA: Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther 2008;10:377-383.
6. Peyrot M, Rubin RR: Patient-reported outcomes for an integrated real-time continuous glucose monitoring/insulin pump system. Diabetes Technol Ther 2009;11:57-62.
7. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dai-ley G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group: Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311-319.
8. Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H, Jeandidier N, Nicolini M : Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care 2009;32:2245-2250.
9. Peyrot M, Rubin RR: Validation and reliability of an instrument for assessing health-related quality of life: the Insulin Delivery System Questionnaire. Diabetes Care 2005; 28:53-58. (Pubitemid 40095782)
10. Hoogma RPLM, Hammond PJ, Gomis R, Kerr D, Brutomesso D, Bouter KP, Wiefels KJ, de la Calle H, Schweitzer DH, Pfohl M, Torlone E, Krinelke LG, Bolli GB; 5-Nations Study Group: Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily injections (MDI) on glycaemic control and quality of life: results of the 5-Nations Trial. Diabet Med 2005;23:141-147.
11. Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR: Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 2003;26:2598-2603. (Pubitemid 37052106)
12. JDRF Research Foundation Continuous Glucose Monitoring Study Group: Quality-of-life measures in children and adults with type 1 diabetes: JDRF Research Foundation Continuous Glucose Monitoring randomized trial. Diabetes Care 2010;33:2175-2177.
13. Rubin RR, Peyrot M: Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump. J Diabetes Sci Technol 2009;3:1402-1410.
14. Ware JE, Kosinski M, Dewey JE: How to Score Version Two of the SF-36 Health Survey. Lincoln, RI: QualityMetric, Inc., 2000.
15. Varni JW, Burwinkle TM, Jacobs JR, Gottschalk M, Kaufman F, Jones KL: The PedsQL in type 1 and type 2 diabetes: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales and type 1 Diabetes Module. Diabetes Care 2003;26:631-637. (Pubitemid 36929319)
16. Gonder-Frederick LA, Schmidt KM, Vajda KA, Greear ML, Singh H, Shepard JA, Cox DJ: Psychometric properties of the Hypoglycemia Fear Survey-II for adults with type 1 diabetes. Diabetes Care 2011;34:801-806.
17. Gonder-Frederick LA, Fisher CD, Ritterband LM, Cox DJ, Hou L, DasGupta AA, Clarke WL: Predictors of fear of hy-poglycemia in adolescents with type 1 diabetes. Pediatr Diabetes 2006;7:215-222. (Pubitemid 44227662)
18. Clarke WL, Gonder-Frederick LA, Snyder AL, Cox DJ: Maternal fear of hypoglycemia in their children with insulin dependent diabetes mellitus. J Pediatr Endocrinol Metab 1998;11(Suppl 1):189-194.
19. Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-592.
20. Rubin RR, Peyrot M, Chen X, Frias JP: Patient-reported outcomes from a 16-week, open label, multicenter study of insulin pump therapy in patients with type 2 diabetes mel-litus. Diabetes Technol Ther 2010;12:901-906.
21. Peyrot M, Rubin RR: Effect of Technosphere inhaled insulin on quality of life and treatment satisfaction. Diabetes Tech-nol Ther 2010;12:49-55.
22. Kamble S, Perry BM, Shafiroff J, Sculman KA, Reed SD: Provider time associated with sensor-augmented insulin pump therapy in type 1 diabetes [abstract]. Diabetes 2011;60(Suppl 1):A238.
23. Rubin RR, Borgman SK, Sulik BT: Crossing the technology divide: practical strategies for transitioning patients from multiple daily injections to sensor-augmented pump therapy. Diabetes Educ 2011;37(Suppl 1):5s-18s.